Proteus mirabilis
Proteus mirabilis[edit]
Overview[edit]
Proteus mirabilis is a Gram-negative, facultatively anaerobic bacterium known for its swarming motility and urease activity. It is part of the normal flora of the human gastrointestinal tract but can cause urinary tract infections (UTIs) and other opportunistic infections. This organism is notable for its ability to rapidly spread across solid surfaces, forming distinctive concentric rings.
Classification[edit]
- Kingdom: Bacteria
- Phylum: Proteobacteria
- Class: Gamma Proteobacteria
- Order: Enterobacterales
- Family: Enterobacteriaceae
- Genus: Proteus
- Species: P. mirabilis
Characteristics[edit]
P. mirabilis exhibits several distinctive traits:
- Swarming Motility: Ability to move in a coordinated manner on solid surfaces.
- Urease Production: Enzymatic conversion of urea into ammonia and carbon dioxide, increasing the pH of its environment.
- Gram-Negative: Characterized by a thin peptidoglycan layer and an outer membrane containing lipopolysaccharides.

Pathogenicity[edit]
While P. mirabilis is a common part of the gut flora, it can cause infections when it enters sterile areas of the body. It is a significant cause of UTIs, particularly in catheterized patients. Other infections include:
- Kidney stones: Due to urease activity, leading to alkaline urine and the formation of struvite stones.
- Wound infections
- Respiratory tract infections
Diagnosis[edit]
Diagnosis of P. mirabilis infections involves:
- Urine or blood cultures
- Identification of characteristic swarming on agar plates
- Urease tests
- Gram staining
Treatment[edit]
Treatment typically involves antibiotics, though P. mirabilis shows resistance to many common antibiotics. Options include:
- Nitrofurantoin
- Fluoroquinolones
- Third-generation cephalosporins
- Prevention of UTIs involves proper catheter care and hygiene practices.
Research and Epidemiology[edit]
Research on P. mirabilis focuses on understanding its resistance mechanisms, developing new antibiotics, and preventing infections in hospital settings. Epidemiological studies track its prevalence in healthcare facilities and the community.
See Also[edit]
References[edit]
- National Center for Biotechnology Information (NCBI)
- Centers for Disease Control and Prevention (CDC)
External Links[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian